Targeting high circulating dipeptidyl peptidase 3 in circulatory failure

Figures

• 

  Fig. 1. Current understanding of the mode of action of cDPP3 and procizumab in circulatory failure. The upper part of the figure illustrates the pathogenic effects of high cDPP3, which excessively cleave angiotensin II, contributing to vasodilation, hypotension, and acute kidney injury. The lower part depicts the therapeutic action of procizumab, which inhibits cDPP3 activity, preserves angiotensin II, thereby stabilizing systemic and renal hemodynamics. (c)DPP3: (circulating) dipeptidyl peptidase 3

• 

  Fig. 2. Distribution of circulating dipeptidyl peptidase 3 (cDPP3) concentration across cohorts of ambulatory individuals with relative frequency indicating the proportion of individual in each population with a given cDPP3 concentration (A), influence of sex (B) and age (C). The “healthy” population (n = 120) consists of individuals who are free of detectable pathology and are not receiving any medication. The “reference” population (n = 8,849) includes ambulatory individuals who may present with comorbidities and chronic treatments, reflecting the baseline characteristics of patients likely to be admitted to the intensive care unit. Details about cohorts included in this analysis can be found in the supplemental table. cDPP3: circulating dipeptidyl peptidase 3

• 

  Fig. 3. Distribution of circulating dipeptidyl peptidase 3 (cDPP3) concentration and its association with clinical outcomes in patients with circulatory failure, based on a meta-analysis of seven studies (1,310 patients): relative frequency of individuals in each populations with a given cDPP3 concentration, and proportion (%) of patients higher than the 30 ng/ml cut-off corresponding to the 95th percentile of a reference population (A), survival (B) and need for organ support (C) according to cDPP3. Patients who did not survive were systematically categorized as having required organ support. Details about cohorts included in this analysis can be found in the supplemental table. cDPP3: circulating dipeptidyl peptidase 3; RRT: Renal replacement therapy